This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

NCT06853223 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Primary Graft Dysfunction
Lung Transplantation
Acute Lung Injury(ALI)
Natural Killer Cell Mediated Immunity

Interventions

DRUG: Maraviroc
DRUG: Placebo

Sponsor

University of California, San Francisco

Collaborators

[object Object]